摘要
新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)是由冠状病毒2(Severe Acute Respiratory Syndrome Coronavirus 2,SARS-CoV-2)引起的急性呼吸窘迫综合征,具有传染性。COVID-19肺炎病程分为潜伏期、症状明显期、炎症高反应期和缓解期。佩戴口罩和严格隔离、出行限制是控制疫情的重要措施。根据COVID-19的病理特征和不同的临床阶段,抗病毒药、免疫调节剂、低分子量肝素、恢复期血浆以及干细胞治疗等是现代医学的主要治疗方法。中西医学结合理论发展使得中医能够以新型医学模型探讨COVID-19肺炎形成的病机,即木旺生火、木火通明,相应的出现水行、土行和金行虚衰。西药多归属于中医的清热解毒药物,干细胞治疗则属于补肾疗法。中医根据COVID-19肺炎病机,按照温补肾阳、健脾行气的基本原则制定方剂,并应用于COVID-19肺炎的防治过程中。COVID-19肺炎属于寒湿疫,可以按照《伤寒论》六经理论可以分为太阳病期、阳明病期、少阳病期、太阴病期、少阴病期和厥阴病期。相关研究需要进一步探讨。
Coronavirus disease 2019(COVID-19)is an infectious disease caused by coronavirus-2(SARS-CoV-2)that causes a severe acute respiratory syndrome,four stages of COVID-19 have been identified:incubation,symptomatic infection,hyperinflammation and resolution.Wearing masks,strict isolation,and travel restrictions are important measures to prevent the pandemic of COVID-19.Based on the pathological features and different clinical phases of COVID-19,the classes of drugs used are antiviral agents,inflammation inhibitors,low molecular weight heparins,plasma,and mesenchymal stem cell.In recent years,two novel medical models are presented,which are beneficial for the integration of TCM and modern medicine and take some novel insights of COVID-19 pneumonia.So,pathogenesis of COVID-19 pneumonia can be abstracted as robustness of wood^(TCM) and fire^(TCM) with the weakness of water^(TCM),earth^(TCM) and metal^(TCM).Most of drugs for COVID-19 should be classified as antipyretic-detoxicate drugs and stem cell therapy should be regarded to tonify the kidney^(TCM).According to the pathogenesis of COVID-19 pneumonia,tonifying kidney^(TCM),spleen^(TCM) and lung^(TCM) are the principles to treat COVID-19.In TCM,cold and dampness are regarded as the causality of COVID-19 pneumonia and six stages should be identified according to the theory of Shanghanlun(《伤寒论》):Taiyang(太阳)disease,Yangming(阳明)disease,Shaoyang(少阳)disease,Taiying(太阳)disease,Shaoyin(少阴)disease and Jueying(厥阴)disease.More researches should be carried out.
作者
肖党生
方辉
杨介钻
应佩君
XIAO Dangsheng;FANG Hui;YANG Jiezuan;YING Peijun
出处
《中医临床研究》
2021年第36期30-34,共5页
Clinical Journal Of Chinese Medicine
